Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?

BACKGROUND The ageing of populations makes outcome monitoring among elderly cancer patients particularly important. PATIENTS AND METHODS Using data from the population-based Cancer Registry of Saarland, we examined age-specific trends in 5-year relative survival from 1979 to 2003 for patients with 15 common cancers in Germany. Model-based period analysis was applied to estimate 5-year relative survival for four age groups (15-54, 55-64, 65-74, 75+) in the periods 1979-1983, 1984-1988, 1989-1993, 1994-1998, and 1999-2003. RESULTS Overall, 5-year relative survival improved steadily from 42.2% in 1979-1983 to 56.7% in 1999-2003. From the youngest to the oldest age group, 5-year relative survival increased by 14.5, 12.1, 12.5, and 8.4 percent units, respectively, after adjusting for changes in the spectrum of cancer sites, and survival significantly improved for 10, 12, 11, and 5 cancer sites, respectively. The age gradient particularly increased for cancer sites with major progress in chemotherapeutic treatment regimens, such as ovarian cancer, non-Hodgkin's lymphoma and leukemia. CONCLUSIONS Relative survival of cancer patients increased considerably for many forms of cancer in Germany from 1979 to 2003. Increases were much less pronounced among elderly patients, leading to an increasing age gradient in prognosis.

[1]  C. Garbe,et al.  Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976–2001 , 2007, Cancer.

[2]  H. Brenner,et al.  Up-to-date and precise estimates of cancer patient survival: model-based period analysis. , 2006, American journal of epidemiology.

[3]  W. Mcguire Is it time for some new approaches for treating advanced ovarian cancer? , 2006, Journal of the National Cancer Institute.

[4]  H Brenner,et al.  Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. Kitchener,et al.  Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Monfardini,et al.  Colorectal cancer adjuvant treatment in elderly patients. , 2005, Critical reviews in oncology/hematology.

[7]  T. Wasil,et al.  Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. , 2005, The oncologist.

[8]  H. Brenner,et al.  Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Coebergh,et al.  Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. , 2005, European journal of cancer.

[10]  M. Janssen-Heijnen,et al.  The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. , 2005, Gynecologic oncology.

[11]  L. Weissbach,et al.  Systematic development of a guideline for early detection of prostate cancer: the German way in the evidence gap. , 2004, European urology.

[12]  H. Brenner,et al.  Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient , 2004, Cancer Causes & Control.

[13]  A. du Bois,et al.  Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[14]  H. Brenner,et al.  An alternative approach to age adjustment of cancer survival rates. , 2004, European journal of cancer.

[15]  Magnus Stenbeck,et al.  Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data. , 2004, European journal of cancer.

[16]  R. Yancik,et al.  Cancer in older persons: an international issue in an aging world. , 2004, Seminars in oncology.

[17]  H Brenner,et al.  Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. , 2004, European journal of cancer.

[18]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[19]  F Berrino,et al.  EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Coleman,et al.  EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Becker Epidemiological aspects of cancer screening in Germany , 2003, Journal of Cancer Research and Clinical Oncology.

[22]  R. Cress,et al.  Patterns of chemotherapy use for women with ovarian cancer: a population-based study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Joy H. Lewis,et al.  Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Stone,et al.  The Difficult Problem of Acute Myeloid Leukemia in the Older Adult , 2002, CA: a cancer journal for clinicians.

[25]  H. Lippert,et al.  Impact of age on the short-term postoperative outcome of patients undergoing surgery for colorectal carcinoma , 2002, International Journal of Colorectal Disease.

[26]  G Dhom,et al.  Patient delay and stage of diagnosis among breast cancer patients in Germany – a population based study , 2002, British Journal of Cancer.

[27]  Hermann Brenner,et al.  Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. , 2002, International journal of epidemiology.

[28]  C. Meisner,et al.  Primary breast cancer therapy in six regions of Germany. , 2002, European journal of cancer.

[29]  H. Brenner,et al.  Up-to-date long-term survival curves of patients with cancer by period analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Monfardini,et al.  Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy. , 2001, Critical reviews in oncology/hematology.

[31]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[32]  H. Brenner,et al.  Socio-demographic factors, health behavior and late-stage diagnosis of breast cancer in Germany: a population-based study. , 2001, Journal of clinical epidemiology.

[33]  R. Yancik,et al.  Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Carbone,et al.  Advances in the systemic treatment of cancers in the elderly. , 2000, Critical reviews in oncology/hematology.

[35]  M. Coleman,et al.  Toward a comparison of survival in American and European cancer patients , 2000, Cancer.

[36]  J. Coebergh,et al.  Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. , 1999, Journal of clinical epidemiology.

[37]  S. Monfardini,et al.  A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. , 1999, European journal of cancer.

[38]  P. Littlejohns,et al.  Factors predicting delayed presentation of symptomatic breast cancer: a systematic review , 1999, The Lancet.

[39]  S. Parodi,et al.  Relative survival in elderly cancer patients in Europe. EUROCARE Working Group. , 1998, European journal of cancer.

[40]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[41]  J. Samet,et al.  Determinants of cancer therapy in elderly patients , 1993, Cancer.

[42]  Harold C. Sox,et al.  National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .

[43]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.

[44]  H. Dienemann,et al.  [Therapy in elderly patients]. , 2008, Onkologie.

[45]  B. Thiers Generalizability of Cancer Clinical Trial Results: Prognostic Differences between Participants and NonparticipantsElting LS, Cooksley C, Bekele BN, et al (Univ of Texas, Houston) Cancer 106:2452–2458, 2006§ , 2007 .

[46]  M. Rosén,et al.  Cancer patient survival in Sweden at the beginning of the third millennium – predictions using period analysis , 2004, Cancer Causes & Control.

[47]  Cancer incidence in five continents. Volume VIII. , 2002, IARC scientific publications.

[48]  O. Gefeller,et al.  An alternative approach to monitoring cancer patient survival. , 1996, Cancer.

[49]  H Brenner,et al.  Estimating completeness of cancer registration in Saarland/Germany with capture-recapture methods. , 1994, European journal of cancer.

[50]  W. Luppold,et al.  The Residue Determinant , 2004, math/0406268.